<DOC>
	<DOCNO>NCT00065676</DOCNO>
	<brief_summary>Quercetin compound naturally find various food . It may role treatment obesity diabetes . The purpose study investigate research volunteer obesity obesity type 2 diabetes determine whether quercetin affect way glucose absorb body . Thirty two participant age 19 65 consider medically obese obese type 2 diabetes enrol study . Before onset treatment , undergo medical history , physical exam , blood work , urinalysis . During study , participant give oral glucose tolerance test three time ; test receive 1 2 gram quercetin , placebo . Researchers collect blood sample analyze effect treatment blood glucose .</brief_summary>
	<brief_title>Investigating Use Quercetin Glucose Absorption Obesity , Obesity With Type 2 Diabetes</brief_title>
	<detailed_description>Postprandial hyperglycemia resultant hyperinsulinemia contribute cardiovascular complication see obesity type 2 diabetes . Epidemiological study suggest slow absorption carbohydrate dampen glucose insulin peak , reduces cardiovascular morbidity . The polyphenol quercetin abundant flavanoid plant-derived food , sell dietary supplement . In vitro , quercetin potent reversible inhibitor glucose transport intestinal glucose transporter GLUT2 . In vivo quercetin inhibits post absorptive glucose peak obese , diabetic rat . We hypothesize quercetin blunts intestinal glucose absorption human , attenuate postprandial hyperglycemia . We propose test , double blind placebo control study , whether coadministration 1 2 gram quercetin glucose reduce plasma glucose concentration 6 hour oral glucose tolerance test 3 6 gram 3-O-methyl glucose ( 3OMG ) non-diabetic obese subject obese type 2 diabetic subject . The glucose dose may vary 0 100 gram well understand competition 3OMG glucose . 3OMG non-metabolizable glucose analogue excrete unaltered urine . 3OMG find food thus glucose absorption study easily without problem high baseline value . The use 3OMG provide accurate true measure glucose absorption . Study subject 19 - 65 year body mass index great equal 30 , without complication diabetes , medication oral hypoglycemic agent aspirin . We study 16 obese non diabetic subject 16 obese type 2 diabetic . Each subject 3 oral glucose tolerance test , serve control . We compare peak plasma glucose concentration achieve oral glucose tolerance test area curve plasma glucose determine whether quercetin inhibits glucose absorption human . Such inhibition may partially explain protective effect plant derive food cardiovascular disease , enable u use quercetin related compound dampen intestinal glucose absorption . We also measure quercetin concentration plasma , circulate white blood cell urine determine quercetin pharmacokinetics . Additionally , determine optimal 3OMG dose , study absorption glucose 3OMG , without quercetin , 12 non-diabetic obese subject 12 lean subject serve control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Quercetin</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects recruit study male female subject age 18 65 , able give inform consent , mild moderate type 2 diabetes ( fast blood sugar &lt; 200mg/dl HbA1C &lt; 8.5 ) , otherwise good general health , significant illness , blood pressure &lt; =160/90 mmHg without medication , know severe target organ damage . End organ damage include follow : proliferative retinopathy , serum creatinine &gt; 2 , ischemic heart disease , congestive heart failure , peripheral vascular disease severe peripheral neuropathy . Diabetic subject must BMI great equal 30 . Subjects take hypoglycemic agent 3 7 day prior part study . This remove confound factor may affect blood glucose concentration attain OGTT , independent effect quercetin . Whether oral hypoglycemic agent physiologically significant interaction quercetin know . During time subject oral hypoglycemic agent , monitor fast blood glucose daily glucometer . Therefore , subject diabetes , subject selfmonitor blood glucose eligible inclusion . If fasting blood glucose morning exceed 300 mg/dl , subject withdrawn study appropriate therapy resume . Obese volunteer , BMI great equal 30 , must good health , know illness . Healthy , normal weight subject ( BMI &lt; 25 ) also recruit control subject sample study without querecetin . An upper age limit 65 year choose minimize renal toxicity quercetin , GFR decline age quercetin might produce mild though reversible renal impairment . EXCLUSION CRITERIA : Exclusion criterion include follow : significant digestive abnormality malabsorption chronic diarrhea ; significant organ malfunction include ( limited ) liver disease , pulmonary disease , ischemic heart disease , heart failure , stroke , peripheral vascular disease , hypertension ( BP &gt; 160/90 ) , anemia ( hematocrit &lt; 30 ) ; serious chronic illness ; history serious chronic illness ; significant complication diabetes kidney damage ( renal insufficiency , serum creatinine &gt; 2 ) , eye damage ( proliferative retinopathy ) , severe diabetic neuropathy , coronary artery disease , symptomatic peripheral vascular disease ; smoking ; alcohol drug abuse ; smoker ; pregnancy ( urine pregnancy test perform woman reproductive age part study ) ; positive HIV hepatitis ( B C ) screen test ( subject notify test result ) . Diabetic subject choose selfmonitor glucose daily glucometer exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 29, 2016</verification_date>
	<keyword>Hyperglycemia</keyword>
	<keyword>Hyperinsulinemia</keyword>
	<keyword>OGTT</keyword>
	<keyword>GLUT2</keyword>
	<keyword>Post-Prandial</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Obesity</keyword>
</DOC>